Generali Investments Management Co LLC Has $3.37 Million Position in Stryker Corporation $SYK

Generali Investments Management Co LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 15.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,122 shares of the medical technology company’s stock after selling 1,700 shares during the period. Stryker accounts for 0.7% of Generali Investments Management Co LLC’s investment portfolio, making the stock its 27th biggest holding. Generali Investments Management Co LLC’s holdings in Stryker were worth $3,372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYK. Brighton Jones LLC lifted its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. acquired a new stake in Stryker during the second quarter valued at approximately $205,000. Daymark Wealth Partners LLC grew its position in Stryker by 7.4% in the second quarter. Daymark Wealth Partners LLC now owns 7,306 shares of the medical technology company’s stock valued at $2,890,000 after acquiring an additional 501 shares during the period. Arkadios Wealth Advisors grew its holdings in shares of Stryker by 17.2% in the 2nd quarter. Arkadios Wealth Advisors now owns 4,747 shares of the medical technology company’s stock worth $1,878,000 after purchasing an additional 695 shares during the last quarter. Finally, Premier Path Wealth Partners LLC grew its stake in Stryker by 4.4% during the second quarter. Premier Path Wealth Partners LLC now owns 1,746 shares of the medical technology company’s stock worth $691,000 after buying an additional 73 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on SYK. TD Cowen cut shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research report on Monday, January 26th. Citizens Jmp upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price on the stock in a report on Friday, December 19th. Barclays reissued an “overweight” rating and issued a $469.00 price target on shares of Stryker in a research note on Monday, February 2nd. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Robert W. Baird set a $437.00 target price on shares of Stryker in a research note on Friday, January 30th. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $426.47.

Stryker Trading Up 0.5%

Shares of NYSE:SYK opened at $386.04 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $404.87. The company has a market capitalization of $147.73 billion, a P/E ratio of 45.96, a P/E/G ratio of 2.24 and a beta of 0.87. The business’s 50 day simple moving average is $362.53 and its 200 day simple moving average is $369.14.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter in the prior year, the business posted $4.01 earnings per share. Stryker’s revenue was up 11.4% compared to the same quarter last year. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is 41.90%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.